RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary
BioSyent Pharma Inc. has secured two long-term hospital supply contracts for its
recently launched Cathejell(TM) Jelly 2%.


One supply agreement is for a three year period, ending in June 2015 and the
second agreement is for a four year period ending in June 2016. Shipments to
supply both contracts have commenced. Total volumes under the two contracts are
open ended and give Cathejell(TM) Jelly 2% access to hospitals and healthcare
facilties representing approximately 2/3 of the Canadian market.


"We are pleased with the initial feedback from urologists and other health care
professionals to the Cathejell(TM) Jelly 2% launch. They clearly see the
benefits of our product relating to patient safety and ease of use", commented
Rene Goehrum, President and CEO of BioSyent. "These contracts will provide a
platform for us to build this brand in Canada for years to come".


Cathejell(TM) Jelly 2% is an innovative pharmaceutical product that combines a
sterile gel and lidocaine in a unique collapsible applicator syringe which
provides a safe and effective solution for healthcare professionals and patients
to ease the discomfort of a range of medical procedures.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking.  The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements.  Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024